Exploring genetic and immune underpinnings of the sexual dimorphism in tumor response to immune checkpoints inhibitors: A narrative review
- PMID: 36571078
- PMCID: PMC9772791
- DOI: 10.1016/j.crphar.2022.100146
Exploring genetic and immune underpinnings of the sexual dimorphism in tumor response to immune checkpoints inhibitors: A narrative review
Abstract
Introduction: In spite of the undisputed relevance of sex as critical biologic variable of the immune landscape, still limited is our understanding of the basic mechanisms implicated in sex-biased immune response thereby conditioning the therapeutic outcome in cancer patients. This hindrance delays the actual attempts to decipher the heterogeneity of cancer and its immune surveillance, further digressing the achievement of predictive biomarkers in the current immunotherapy-driven scenario. Body: The present review concisely reports on genetic, chromosomal, hormonal, and immune features underlying sex-differences in the response to immune checkpoint inhibitors (ICIs). In addition to outline the need of robust data on ICI pharmaco-kinetics/dynamics, our survey might provide new insights on sex determinants of ICI efficacy and suggests uncovered pathways that warrant prospective investigations.
Conclusion: According to a sharable view, we propose to widely include sex among the co-variates when assessing the clinical response to ICI in cancer patients.
Keywords: Cancer patients; Genetic background; Immune checkpoint inhibitors; Immune response; Sex; Sex differences.
© 2022 Published by Elsevier B.V.
Conflict of interest statement
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
References
-
- Ahnstedt Hilda, Roy-O’Reilly Meaghan, Spychala Monica S., Mobley Alexis S., Bravo-Alegria Javiera, Chauhan Anjali, Aronowski Jaroslaw, Marrelli Sean P., McCullough Louise D. Sex differences in adipose tissue CD8 + T cells and regulatory T cells in middle-aged mice. Front. Immunol. 2018;9(APR) doi: 10.3389/FIMMU.2018.00659. - DOI - PMC - PubMed
-
- Altorki Nasser K., Markowitz Geoffrey J., Gao Dingcheng, Port Jeffrey L., Saxena Ashish, Stiles Brendon, McGraw Timothy, Mittal Vivek. The lung microenvironment: an important regulator of tumour growth and metastasis. Nat. Rev. Cancer. 2019;19(1):9–31. doi: 10.1038/s41568-018-0081-9. - DOI - PMC - PubMed
-
- Anagnostou Valsamo, Smith Kellie N., Forde Patrick M., Niknafs Noushin, Bhattacharya Rohit, White James, Zhang Theresa, et al. Evolution of neoantigen landscape during immune checkpoint blockade in non-small cell lung cancer. Cancer Discov. 2017;7(3):264–276. doi: 10.1158/2159-8290.CD-16-0828. - DOI - PMC - PubMed